CARINA: Barriers in Clinical COPD care study (version 1)

  • Research type

    Research Study

  • Full title

    CARINA: Barriers in clinical COPD care study. An international qualitative study to understand current and future barriers in clinical care in people with COPD

  • IRAS ID

    337606

  • Contact name

    Marjan Kerkhof

  • Contact email

    carina@gpri.nl

  • Sponsor organisation

    AstraZeneca UK

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    0 years, 6 months, 18 days

  • Research summary

    Chronic obstructive pulmonary disease (COPD) is a progressive lung disease, that causes obstructed airflow from the lungs leading to breathing difficulty. Despite the availability of effective treatment options, evidence suggests that available therapies may not be utilised to their full potential. We aim to interview 60 persons with COPD, who are at risk of flare-ups, across 5 different countries (UK, Netherlands, USA, Australia, China) to learn more about the perspectives of people with COPD on their current COPD care, and the nature and impact of barriers they experience in accessing better care.
    Candidate participants will be recruited through pharmacies when inhalers or medication for treatment of a flare-up (prednisolone or antibiotics) are given.
    Alternatively, they may be actively approached by the pharmacist based on a registered prescription of inhaler medication. Recruitment for this study will be combined with recruitment for another interview study on the impact of asthma on daily life. A flyer will be given to subjects inviting them to visit a website with information about both studies.
    An online screenings questionnaire will be used to assess eligibility for inclusion.
    When candidates confirm that they are interested, they will be led to a secure online platform where they can sign a form giving their consent to complete a short questionnaire on their diagnosis, disease severity and medication use. When the answers indicate that the candidate is eligible for inclusion, an invitation will be sent by e-mail that leads to a second round of an electronic informed consent procedure to include the patient in the study.
    In the UK, a total of 12 patients who have given their informed consent and contact details will be approached for an online interview of one hour that will be recorded. Recordings will be uploaded on a secure server, transcribed and pseudonomised for analyses.

  • REC name

    North West - Greater Manchester Central Research Ethics Committee

  • REC reference

    24/NW/0005

  • Date of REC Opinion

    13 Feb 2024

  • REC opinion

    Further Information Favourable Opinion